Leap Therapeutics Inc (LPTX)

$2.8

+0.13

(+4.67%)▲

Live

Performance

  • $2.53
    $2.81
    $2.80
    downward going graph

    9.64%

    Downside

    Day's Volatility :10.03%

    Upside

    0.43%

    downward going graph
  • $1.31
    $5.00
    $2.80
    downward going graph

    53.18%

    Downside

    52 Weeks Volatility :73.78%

    Upside

    44.0%

    downward going graph

Returns

PeriodLeap Therapeutics IncIndex (Russel 2000)
3 Months
26.78%
0.0%
6 Months
-16.67%
0.0%
1 Year
83.22%
0.0%
3 Years
-90.81%
-23.0%

Highlights

Market Capitalization
89.2M
Book Value
$1.72
Earnings Per Share (EPS)
-0.98
PEG Ratio
0.75
Wall Street Target Price
11.38
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-45.62%
Return On Equity TTM
-80.54%
Revenue TTM
375.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
1.5M
EBITDA
-64.7M
Diluted Eps TTM
-0.98
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.81
EPS Estimate Next Year
-1.25
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Leap Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 306.43%

Current $2.80
Target $11.38

Technicals Summary

Sell

Neutral

Buy

Leap Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Leap Therapeutics Inc
Leap Therapeutics Inc
-1.29%
-16.67%
83.22%
-90.81%
-76.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Leap Therapeutics Inc
Leap Therapeutics Inc
NA
NA
0.75
-1.81
-0.81
-0.46
NA
1.72
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Leap Therapeutics Inc
Leap Therapeutics Inc
Buy
$89.2M
-76.54%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Leap Therapeutics Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 5.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 135.6%

Institutional Holdings

  • Balyasny Asset Management LLC

    8.10%

  • Samsara BioCapital, LLC

    6.38%

  • 683 Capital Management LLC

    3.40%

  • Rock Springs Capital Management LP

    3.31%

  • Baker Bros Advisors LP

    3.06%

  • Vanguard Group Inc

    2.60%

Company Information

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.

Organization
Leap Therapeutics Inc
Employees
54
CEO
Mr. Douglas E. Onsi J.D.
Industry
Health Technology

Discover More

FAQs